Erica DiNapoli

Lan G. Coffman, MD, PhD, discusses the role of genetic testing in breast and gynecologic cancers and the many advances made with targeted therapies.

Vignesh Narayanan, MD, the role of chemoimmunotherapy and how it has truly changed the game in the treatment of patients with lung cancer.

Jordan D. Berlin, MD, discusses the unmet needs in pancreatic cancer treatment and ongoing research efforts with nanoliposomal irinotecan.

Vincent J. Picozzi Jr, MD, spotlights the launch of PanCAN’s Precision Promise clinical trial platform, and how it is expected to impact clinical practice.

Joshua Reuss, MD, discusses the lung cancer armamentarium, the role of immunotherapy combinations, and the significance of biomarkers.

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

Alan P. Z. Skarbnik, MD, breaks down factors that should be kept in mind when navigating the complex chronic lymphocytic leukemia armamentarium as it relates to BTK inhibitors.

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.

Weijing Sun, MD, FACP, discusses the great need for effective first-line treatment options in advanced/metastatic gastric and GEJ adenocarcinoma.

Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, discusses the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

Julie M. Collins, MD, MPH, highlights key updates with targeted agents such as CDK4/6 and PI3K inhibitors in the treatment of patients with hormone receptor–positive breast cancer.

Balazs Halmos, MD, MS, highlights the significance of the ADAURA trial in EGFR-positive NSCLC, questions raised by these data, and other efforts being made in the adjuvant setting.

Mae Zakhour, MD, discusses the rise of PARP inhibitors as frontline maintenance therapy in advanced ovarian cancer and the key data that supported these regulatory decisions.

Antoinette R. Tan, MD, discusses the FDA approval of the fixed-dose combination of SC pertuzumab and trastuzumab with hyaluronidase, in combination with IV chemotherapy in HER2-positive breast cancer.

Jason J. Luke, MD, discusses the recent advancements with BRAF-targeted therapies and PD-1 checkpoint inhibitors in melanoma.

Renato G. Martins, MD, discusses the many up-front approaches that have emerged in NSCLC, remaining questions to address with future efforts, and novel combinations under exploration.

Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level.

Christina Baik, MD, MPH, highlights the evolving role of EGFR inhibition in the NSCLC space.

Abhinav Deol, MD, highlights the progress that has been made with CAR T-cell therapy in leukemia and lymphoma, challenges faced with regard to accessibility and toxicity, and next steps for this modality.

Jeffrey Zonder, MD, discusses the explosion of targeted therapies, along with the rise of cellular therapy, in hematologic malignancies.

In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.

In a special episode of OncLive On AirTM Vivek Subbiah, MD, discusses the FDA approval of pembrolizumab in TMB-high solid tumors and addressed the controversy surrounding the approval.

Neal D. Shore, MD, FACS, highlights the role of darolutamide plus androgen deprivation therapy and how it continues to demonstrate a highly favorable tolerability and safety profile in patients with nonmetastatic castration-resistant prostate cancer.

Amir Goldkorn, MD, discusses circulating tumor cell count, a beneficial biomarker in patients with metastatic castration-sensitive prostate cancer.

Daniel P. Petrylak, MD, discusses the ever-changing prostate cancer armamentarium, as well as the role of biomarkers and new diagnostic methods in the space.

Seema A. Bhat, MD, spotlights the advances that have been made with BTK inhibitors in chronic lymphocytic leukemia, shares emerging approaches under exploration, and forecasts where the field is headed.

Sarah Nagle, MD, spotlights the critical role of targeted therapy in multiple myeloma.